Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GLS | O94925 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241938 | 0.88 | POLB (0.57) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL14977428 | 0.81 | ALDH1A1 (0.86) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL14975757 | 0.81 | ALDH1A1 (0.95) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL1968819 | 0.79 | ALDH1A1 (0.88) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL15709879 | 0.79 | ALDH1A1 (1.00) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL14986945 | 0.79 | ALDH1A1 (1.00) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL16327123 | 0.78 | ALDH1A1 (0.36) | POLBALDH1A1GLSSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20475888 | 0.78 | ALDH1A1 (0.85) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL10954828 | 0.78 | ALDH1A1 (0.72) | POLBALDH1A1GLSL3MBTL1GAA | |
| SCHEMBL1241280 | 0.77 | HRH3 (0.40) | POLBALDH1A1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | POLB 3310/4885ALDH1A1 3224/4885GLS 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.